Literature DB >> 19716264

Meta-analysis provides evidence-based effect sizes for a cancer-specific quality-of-life questionnaire, the FACT-G.

Madeleine T King1, Martin R Stockler, David F Cella, David Osoba, David T Eton, Joanna Thompson, Amy R Eisenstein.   

Abstract

OBJECTIVE: To compare Cohen's guidelines for small (0.2), medium (0.5), and large (0.8) effect sizes with empirical estimates for a cancer-specific health-related quality-of-life questionnaire (HRQOL), the Functional Assessment of Cancer Therapy - General (FACT-G).
METHODS: Seventy-one papers satisfied inclusion criteria for meta-analysis. Blinded to the HRQOL results, three "experts" (with expertise in interpreting the FACT-G questionnaire and managing cancer patients), predicted the relative magnitude of HRQOL mean differences. Size classes (small, medium, large) were defined in terms of relevance to clinical decision making. The experts worked independently and based their predictions on patient characteristics and clinical circumstances. Their judgments were linked with FACT-G results and inverse-variance-weighted mean effect sizes calculated for each size class.
RESULTS: At least two experts were perfectly concordant and up to one was discordant by at most one size category for 833 of the mean differences; for these, weighted kappas were generally in the "substantial" range (0.60-0.79). Of these mean differences, 617 were cross-sectional; small, medium, and large mean effect sizes were physical well-being 0.42, 0.87, 1.6; functional well-being 0.37, 0.71, 1.6; emotional well-being 0.32, 0.40, no large differences; and social well-being 0.14, 0.23, no large differences. Two hundred and sixteen longitudinal mean differences yielded small and medium effect sizes: physical well-being 0.26, 0.34; functional well-being 0.14, 0.28; emotional well-being 0.27, 0.23; and social well-being 0.08, 0.01. There was virtually no evidence for large longitudinal effects.
CONCLUSION: These results provide specific, evidence-based alternatives to Cohen's generic guidelines, for use in sample-size calculations for the FACT-G and interpretation of the clinical significance of effects measured with FACT-G.

Entities:  

Mesh:

Year:  2009        PMID: 19716264     DOI: 10.1016/j.jclinepi.2009.05.001

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  13 in total

Review 1.  A review and recommendations for optimal outcome measures of anxiety, depression and general distress in studies evaluating psychosocial interventions for English-speaking adults with heterogeneous cancer diagnoses.

Authors:  Tim Luckett; Phyllis N Butow; Madeleine T King; Mayumi Oguchi; Gaynor Heading; Nadine A Hackl; Nicole Rankin; Melanie A Price
Journal:  Support Care Cancer       Date:  2010-07-02       Impact factor: 3.603

2.  Which quality of life instruments are preferred by cancer patients in Japan? Comparison of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 and the Functional Assessment of Cancer Therapy-General.

Authors:  Kazuki Sato; Megumi Shimizu; Mitsunori Miyashita
Journal:  Support Care Cancer       Date:  2014-05-28       Impact factor: 3.603

3.  The impact of chemotherapy-related nausea on patients' nutritional status, psychological distress and quality of life.

Authors:  Carole Farrell; Sarah G Brearley; Mark Pilling; Alex Molassiotis
Journal:  Support Care Cancer       Date:  2012-05-19       Impact factor: 3.603

4.  Chemotherapy induced peripheral neuropathy: the modified total neuropathy score in clinical practice.

Authors:  S Vasquez; M Guidon; E McHugh; O Lennon; L Grogan; O S Breathnach
Journal:  Ir J Med Sci       Date:  2013-07-07       Impact factor: 1.568

5.  Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials.

Authors:  John T Maringwa; Chantal Quinten; Madeleine King; Jolie Ringash; David Osoba; Corneel Coens; Francesca Martinelli; Jurgen Vercauteren; Charles S Cleeland; Henning Flechtner; Carolyn Gotay; Eva Greimel; Martin J Taphoorn; Bryce B Reeve; Joseph Schmucker-Von Koch; Joachim Weis; Egbert F Smit; Jan P van Meerbeeck; Andrew Bottomley
Journal:  Support Care Cancer       Date:  2010-10-01       Impact factor: 3.603

6.  Can Methods Developed for Interpreting Group-level Patient-reported Outcome Data be Applied to Individual Patient Management?

Authors:  Madeleine T King; Amylou C Dueck; Dennis A Revicki
Journal:  Med Care       Date:  2019-05       Impact factor: 2.983

7.  Diminished Utilization of in Vitro Fertilization Following Ovarian Transposition in Cervical Cancer Patients.

Authors:  Sana M Salih; Samet Albayrak; Songwon Seo; Sarah L Stewart; Kristen Bradley; David M Kushner
Journal:  J Reprod Med       Date:  2015 Jul-Aug       Impact factor: 0.142

8.  Psychometric characteristics of the Functional Assessment of Cancer Therapy-General when applied to Brazilian cancer patients: a cross-cultural adaptation and validation.

Authors:  Juliana Alvares Duarte Bonini Campos; Maria Cláudia Bernardes Spexoto; Sergio Vicente Serrano; João Maroco
Journal:  Health Qual Life Outcomes       Date:  2016-01-13       Impact factor: 3.186

9.  Meta-analysis provides evidence-based interpretation guidelines for the clinical significance of mean differences for the FACT-G, a cancer-specific quality of life questionnaire.

Authors:  Madeleine T King; David Cella; David Osoba; Martin Stockler; David Eton; Joanna Thompson; Amy Eisenstein
Journal:  Patient Relat Outcome Meas       Date:  2010-09-23

10.  A nurse- and peer-led support program to assist women in gynaecological oncology receiving curative radiotherapy, the PeNTAGOn study (peer and nurse support trial to assist women in gynaecological oncology): study protocol for a randomised controlled trial.

Authors:  Penelope Schofield; Ilona Juraskova; Rebecca Bergin; Karla Gough; Linda Mileshkin; Meinir Krishnasamy; Kate White; David Bernshaw; Sylvia Penberthy; Sanchia Aranda
Journal:  Trials       Date:  2013-02-11       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.